NCT03158129 2026-04-06
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
71 trialsNCT03377023 2026-04-02
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT03366766 2026-02-20
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT02523469 2026-02-17
ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Medical University of South Carolina
Phase 1/2 Completed
NCT03285321 2026-01-20
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03425331 2026-01-08
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT03215706 2025-12-17
CheckMate 9LA
Bristol-Myers Squibb
Phase 3 Completed
NCT04349267 2025-12-17
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02259621 2025-12-03
NA_00092076
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT02823990 2025-11-10
TG4010 and Nivolumab in Patients With Lung Cancer
University of California, Davis
Phase 2 Completed
NCT02477826 2025-10-30
CheckMate 227
Bristol-Myers Squibb
Phase 3 Completed
NCT04623775 2025-10-20
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT05846646 2025-10-20
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT04025879 2025-10-16
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03573947 2025-10-14
TOP1705
Duke University
Phase 2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT04026412 2025-07-24
CheckMate73L
Bristol-Myers Squibb
Phase 3 Completed
NCT06003075 2025-04-30
Induction Chemo-Nivo in Unresectable Stage III NSCLC
University of Kentucky
Phase 2 Terminated
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT05543629 2025-03-18
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03190174 2025-02-17
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
Phase 1/2 Completed
NCT03081689 2024-12-04
Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Spanish Lung Cancer Group
Phase 2 Completed
NCT02613507 2024-11-19
CheckMate 078
Bristol-Myers Squibb
Phase 3 Completed
NCT03583086 2024-10-08
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT02664181 2024-09-03
PRECISE
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03195491 2024-07-18
CheckMate870
Bristol-Myers Squibb
Phase 3 Completed
NCT03502330 2024-07-03
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Yale University
Phase 1 Completed
NCT02949843 2024-06-28
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
Wake Forest University Health Sciences
Phase 2 Terminated
NCT03001882 2024-05-20
CheckMate 592
Bristol-Myers Squibb
Phase 2 Completed
NCT03117049 2024-05-06
Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)
Ono Pharmaceutical Co. Ltd
Phase 3 Completed
NCT01928576 2024-05-03
NA_00084192
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02954991 2024-04-22
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT05005273 2024-02-28
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT03229278 2023-12-06
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT02864251 2023-09-28
CheckMate722
Bristol-Myers Squibb
Phase 3 Completed
NCT02439450 2023-09-21
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Heat Biologics
Phase 1/2 Completed
NCT02658890 2023-08-28
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03215810 2023-07-24
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02659059 2023-04-05
CheckMate 568
Bristol-Myers Squibb
Phase 2 Completed
NCT02771626 2023-03-17
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
Calithera Biosciences, Inc
Phase 1/2 Terminated
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT02041533 2023-03-02
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Bristol-Myers Squibb
Phase 3 Completed
NCT03663166 2023-02-15
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT02834247 2023-02-08
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Calithera Biosciences, Inc
Phase 1 Terminated
NCT03090737 2022-12-05
CheckMate 907
Bristol-Myers Squibb
Phase 2 Completed
NCT02409368 2022-11-14
Checkmate 171
Bristol-Myers Squibb
Phase 2 Completed
NCT02066636 2022-10-27
CheckMate153
Bristol-Myers Squibb
Phase 3 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT02967133 2022-09-08
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Terminated